News | Cardiac Diagnostics | February 15, 2019

IBM and Broad Institute Launch AI Initiative for Cardiovascular Disease Risk Prediction

New partnership will expand power of polygenic risk scores to help clinicians predict and prevent disease

IBM and Broad Institute Launch AI Initiative for Cardiovascular Disease Risk Prediction

February 15, 2019 — IBM Watson Health and the Broad Institute of MIT and Harvard are launching a research partnership aimed at developing powerful predictive models that will enable clinicians to identify patients at serious risk for cardiovascular disease. This three-year project will incorporate population- and hospital-based biobank data, genomic information, and electronic health records to build upon and expand the predictive power of polygenic scoring. The project will also plan to make insights and tools widely available to the research community, including methods to calculate an individual’s risk of developing common diseases based on millions of variants in the genome.

“I’m excited to build upon the advances we’ve made in polygenic risk scoring utilizing vast amount of genomic data,” said Sekar Kathiresan, director of the Center for Genomic Medicine at Massachusetts General Hospital (MGH) and institute member and director of the Cardiovascular Disease Initiative at the Broad Institute. “By coupling clinical data with genomic data, there is an exceptional opportunity to make polygenic risk scoring more robust and powerful, and ultimately transformative for patient care. Such transformation could never happen without these kinds of partnerships.”

Kathiresan will direct this new initiative along with Anthony Philippakis, chief data officer of the Broad Institute who trained as a cardiologist at Brigham and Women’s Hospital.

In recent years, scientists at the Broad Institute, MGH and Harvard Medical School have advanced a new kind of genome analysis called polygenic risk scores. The scores can identify subsets of the population who have a significantly higher risk of developing serious common diseases, including coronary artery disease, atrial fibrillation or breast cancer.

These tests, which use information from more than 6 million sites of variation in the human genome to ascertain risk for disease, can flag greater likelihood of developing serious conditions well before symptoms appear. Research suggests that up to 25 million people in the U.S. may be at more than triple the normal risk for coronary artery disease, and millions more may be at similar elevated risk for the other conditions, based on genetic variation alone. Such genomic information could allow physicians to find these individuals and intervene to prevent disease.

But more work needs to be done before this research is incorporated into clinical care, and that is the role of this new three-year partnership.

IBM and Broad Institute will expand the power of polygenic scoring by building artificial intelligence (AI)-based models for cardiac disease risk based on genomic information combined with patients' medical records and biomarkers. This project will also incorporate direct feedback from doctors and caregivers, all with the ultimate goal of assimilating such power into the medical system.

“With this new partnership, we have the opportunity to develop new approaches for the understanding and prediction of disease,” said Eric S. Lander, president and founding director of the Broad Institute. “I’m hopeful this will help advance precision medicine for patients.”

For more information: www.ibm.com/watson/health, www.broadinstitute.org

Related Content

AI Could Use EKG Data to Measure Patient's Overall Health Status

Image courtesy of iStock

News | Artificial Intelligence | August 29, 2019
In the near future, doctors may be able to apply artificial intelligence (AI) to electrocardiogram data in order to...
Half of Hospital Decision Makers Plan to Invest in AI by 2021
News | Artificial Intelligence | August 08, 2019
A recent study conducted by Olive AI explores how hospital leaders are responding to the imperative to drive efficiency...
Artificial Intelligence Solution Improves Clinical Trial Recruitment

A nurse examines a patient in the Emergency Department of Cincinnati Children’s, where researchers successfully tested artificial intelligence-based technology to improve patient recruitment for clinical trials. Researchers report test results in the journal JMIR Medical Informatics. Image courtesy of Cincinnati Children’s.

News | Artificial Intelligence | July 31, 2019
Clinical trials are a critical tool for getting new treatments to people who need them, but research shows that...

An example of AI-assisted automation developed by TomTec, where a deep learning algorithm automatically marks the myocardial borders and performs auto quantification This removes time consuming tasks to free up the operator to spend more time with patients and helps make exams more reproducible.

Feature | Artificial Intelligence | July 26, 2019
Intelligent software solutions (aka...
vRad Presents AI Model to Assess Probability of Aortic Dissection
News | Artificial Intelligence | July 01, 2019
vRad (Virtual Radiologic), a Mednax company recently made a scientific presentation, “Screening for Aortic Dissection...
Videos | Artificial Intelligence | June 28, 2019
This is a quick example of how artificial intelligence (AI) is being integrated on the back end of cardiac ultrasound
Third FDA Clearance Announced for Zebra-Med's AI Solution for Brain Bleed Alerts
Technology | Artificial Intelligence | June 19, 2019
Zebra Medical Vision announced it has received its third U.S. Food and Drug Administration (FDA) 510(k) clearance for...
Overlay Init